Business
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -
About this update from Climb Bio, Inc.
[{"type":"image","alt":"Climb Bio, Inc.","displaySize":"","headline":null,"caption":"Climb Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/upR1wQHp9TCZxvAhULaG8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c","width":300,"height":300}},"lazy":false},{"type":"text","content":"Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025","length":169,"tagName":"p"},{"type":"text","content":"CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025","length":81,"tagName":"p"},{"type":"text","content":"Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer","length":126,"tagName":"p"},{"type":"text","content":"Strong Financial Position, with Cash Runway Expected Through 2027","length":65,"tagName":"p"},{"type":"text","content":"WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided business updates.","length":303,"tagName":"p"},{"type":"text","content":"“2025 is a critical year of execution for Climb Bio and we continue to make excellent progress developing a differentiated pipeline targeting immune-mediated diseases with expansive therapeutic and commercial potential,” said Aoife Brennan, President and CEO of Climb Bio. “Our most advanced program, budoprutug, a potential best-in-class anti-CD19 monoclonal antibody designed to treat B-cell mediated diseases, remains on track to initiate clinical studies in ITP and SLE in the coming weeks and in pMN in the second half of 2025. We plan to provide clarity on the anticipated timing of clinical readouts later this year when enrollment dynamics are clearer. In parallel, we are advancing the subcutaneous formulation of budoprutug and subject to regulatory clearance, anticipate initiating a Phase 1 clinical trial in healt...